In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an ...

Obesity is a worldwide problem that is increasing. It also is associated with ocular problems. A recent study found that in addition to weight loss, the newer weight loss medications may provide ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical ...

An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

Pharmacotherapy is an effective, evidence-based treatment for people living with obesity, as part of a long-term, ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...